Trial Profile

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
Indications Multiple organ failure; Sepsis
Focus Adverse reactions
Acronyms P-SOFA-1
Sponsors Enlivex Therapeutics

Most Recent Events

04 Oct 2021 According to an Enlivex Therapeutics media release, the paper was published in collaboration with researchers at Hadassah-Hebrew University Medical Center and The Wohl Institute for Translational Medicine.
04 Oct 2021 According to an Enlivex Therapeutics media release, results from this trial were published in Frontiers in Immunology.
04 Oct 2021 Results (n=10) published in an Enlivex Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com